Home - Products - Tyrosine Kinase - BTK - Ibrutinib deacryloylpiperidine

Ibrutinib deacryloylpiperidine

CAS No. 330786-24-8

Ibrutinib deacryloylpiperidine( IBT4A,5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine )

Catalog No. M22200 CAS No. 330786-24-8

Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG 28 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ibrutinib deacryloylpiperidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
  • Description
    Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    IBT4A,5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    Btk
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    330786-24-8
  • Formula Weight
    303.32
  • Molecular Formula
    C17H13N5O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (82.42 mM)
  • SMILES
    Nc3ncnc4nnc(c2ccc(Oc1ccccc1)cc2)c34
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
molnova catalog
related products
  • G-744

    G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM.

  • Btk inhibitor 2

    Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).

  • Fenebrutinib

    An orally bioavailable, selective, non-covalent and reversible BTK inhibitor with IC50 of 2-9 nM.